[{"orgOrder":0,"company":"DelSiTech","sponsor":"IVERIC bio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"Avacincaptad Pegol","moa":"Complement C5 (CO5)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"DelSiTech \/ DelSiTech","highestDevelopmentStatusID":"10","companyTruncated":"DelSiTech \/ DelSiTech"},{"orgOrder":0,"company":"DelSiTech","sponsor":"DRW Venture Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Entecavir","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DelSiTech","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"DelSiTech \/ DRW Venture Capital LLC","highestDevelopmentStatusID":"1","companyTruncated":"DelSiTech \/ DRW Venture Capital LLC"},{"orgOrder":0,"company":"DelSiTech","sponsor":"DelSiTech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DelSiTech \/ DelSiTech","highestDevelopmentStatusID":"4","companyTruncated":"DelSiTech \/ DelSiTech"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FINLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DST-2105","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"DelSiTech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"DelSiTech \/ Undisclosed"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"DelSiTech \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"DelSiTech \/ Bill & Melinda Gates Foundation"}]